Alnylam Pharmaceuticals, Inc.
    SEC Filings

    |
    |

    All SEC filings by Alnylam Pharmaceuticals, Inc. (ALNY) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.

    Financials

    10-QQuarterly reportView DiffJul 30, 2026
    10-QQuarterly reportView DiffApr 30, 2026
    ARSAnnual report to shareholdersApr 6, 2026
    10-KAnnual reportView DiffFeb 12, 2026
    10-QQuarterly reportView DiffOct 30, 2025
    10-QQuarterly reportView DiffJul 31, 2025
    10-QQuarterly reportView DiffMay 1, 2025
    ARSAnnual report to shareholdersMar 24, 2025
    10-KAnnual reportView DiffFeb 13, 2025
    10-QQuarterly reportView DiffOct 31, 2024

    Events

    8-KAlnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period ProgressJul 30, 2026
    8-KDeparture of Directors or Certain OfficersMay 27, 2026
    8-KAlnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period ProgressApr 30, 2026
    8-KDeparture of Directors or Certain OfficersMar 4, 2026
    8-KAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period ProgressFeb 12, 2026
    8-KAlnylam Launches “alnylam 2030” Strategy to Drive Next Era of Growth and Patient ImpactJan 12, 2026
    8-KAlnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027Dec 11, 2025
    8-KAlnylam Pharmaceuticals Announces Changes to Board of DirectorsDec 3, 2025
    8-KAlnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period ProgressOct 30, 2025
    8-KEntry Into a Material Definitive AgreementOct 3, 2025

    Registrations and Prospectuses

    S-8Registration of securities for employeesFeb 12, 2026
    S-8Registration of securities for employeesFeb 23, 2023
    S-8Registration of securities for employeesFeb 11, 2021
    S-3ASRAutomatic shelf registrationJun 5, 2020
    S-8Registration of securities for employeesFeb 13, 2020
    424B5Prospectus supplement for primary offeringJan 15, 2019
    424B5Prospectus supplement for primary offeringJan 14, 2019
    S-8 POSRegistration of securities for employees (post-effective amendment)Aug 2, 2018
    S-8 POSRegistration of securities for employees (post-effective amendment)Aug 2, 2018
    S-8 POSRegistration of securities for employees (post-effective amendment)Aug 2, 2018

    Proxies

    DEFA14AAdditional proxy soliciting materialsApr 6, 2026
    DEF 14ADefinitive proxyView DiffApr 6, 2026
    DEFA14AAdditional proxy soliciting materialsApr 4, 2025
    DEFA14AAdditional proxy soliciting materialsMar 24, 2025
    DEF 14ADefinitive proxyView DiffMar 24, 2025
    PRE 14APreliminary proxyMar 14, 2025
    DEFA14AAdditional proxy soliciting materialsApr 1, 2024
    DEF 14ADefinitive proxyView DiffApr 1, 2024
    DEFA14AAdditional proxy soliciting materialsApr 3, 2023
    DEF 14ADefinitive proxyView DiffApr 3, 2023

    Other

    UPLOADLetter from SECJun 17, 2025
    CORRESPCorrespondence with SECMay 22, 2025
    UPLOADLetter from SECMay 9, 2025
    UPLOADLetter from SECSep 25, 2024
    CORRESPCorrespondence with SECAug 22, 2024
    UPLOADLetter from SECAug 12, 2024
    CT ORDERConfidential treatment orderFeb 14, 2023
    SEC STAFFSEC staff action: OrderMar 18, 2021
    SEC STAFFSEC staff action: OrderFeb 18, 2021
    CT ORDERConfidential treatment orderJul 5, 2019

    Ownership

    4Pyott David E IJun 3, 2026
    4Cravatt BenjaminJun 3, 2026
    3Cravatt BenjaminJun 3, 2026
    144Notice of proposed sale of securitiesJun 1, 2026
    4Charles Elliott SigalMay 22, 2026
    4Amy W SchulmanMay 22, 2026
    4Colleen F ReitanMay 22, 2026
    4David E I PyottMay 22, 2026
    4Peter N KelloggMay 22, 2026
    4Margaret a HamburgMay 22, 2026